213 272

Cited 16 times in

FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD-L1 Expression and Cell Proliferation

Authors
 Hamadi Madhi  ;  Jeon-Soo Lee  ;  Young Eun Choi  ;  Yan Li  ;  Myoung Hee Kim  ;  Yongdoo Choi  ;  Sung-Ho Goh 
Citation
 ADVANCED SCIENCE, Vol.09(29) : e2202702, 2022-10 
Journal Title
ADVANCED SCIENCE
ISSN
 * 
Issue Date
2022-10
MeSH
Animals ; B7-H1 Antigen ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / genetics ; Cell Proliferation ; Forkhead Box Protein M1 / genetics ; Forkhead Box Protein M1 / therapeutic use ; Humans ; Immune Checkpoint Inhibitors / pharmacology ; Immune Checkpoint Inhibitors / therapeutic use ; Immunotherapy ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / genetics ; Programmed Cell Death 1 Receptor ; RNA, Small Interfering / therapeutic use ; Thiostrepton / therapeutic use ; Treatment Outcome
Keywords
forkhead box protein M1 ; immunotherapy ; lung cancer ; programmed death-ligand 1 ; thiostrepton
Abstract
Programmed death-ligand 1 (PD-L1) is a major target to cancer immunotherapy, and anti-PD-L1 and anti-PD-1 antibody-mediated immunotherapy are being increasingly used. However, immune checkpoint inhibitors (ICIs) are ineffective in treating large tumors and cause various immune-related adverse events in nontarget organs, including life-threatening cardiotoxicity. Therefore, the development of new therapeutic strategies to overcome these limitations is crucial. The focus of this study is the forkhead box protein M1 (FOXM1), which is identified as a potential therapeutic target for cancer immunotherapy and is associated with the modulation of PD-L1 expression. Selective small interfering RNA knockdown of FOXM1 or treatment with thiostrepton (TST) significantly reduces PD-L1 expression in non-small-cell lung cancer (NSCLC) cells and inhibits proliferation. Chromatin immunoprecipitation-PCR reveals that FOXM1 selectively upregulates PD-L1 expression by binding directly to the PD-L1 promoter. In vivo animal studies have shown that TST treatment significantly downregulates PD-L1 expression in human NSCLC tumors, while greatly reducing tumor size without side effects on normal tissues. Combined treatment with TST and anti-4-1BB antibody in the LLC-1 syngeneic tumor model induces synergistic therapeutic outcomes against immune resistant lung tumors as well as 2.72-folds higher CD3+ T cells in tumor tissues compared to that in the anti-4-1BB antibody treatment group.
Files in This Item:
T202204553.pdf Download
DOI
10.1002/advs.202202702
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Anatomy (해부학교실) > 1. Journal Papers
Yonsei Authors
Kim, Myoung Hee(김명희) ORCID logo https://orcid.org/0000-0001-5652-1452
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/192155
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links